rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CRVO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia

      24-Week interim data shows neflamapimod delivered an exposure-dependent reduction in neurofilament light chain, a key biomarker of neuronal damage Full 24-week biomarker and clinical data expected in the first quarter of 2027 Nonfluent variant primary progressive aphasia is a rare progressive neurodegenerative brain condition with no approved disease modifying treatments BOSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company) today presented 24-week bioma

      Nov 16Yahoo FinanceCRVO
      CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
      Nov 9Yahoo FinanceCRVO
      CervoMed publishes phase 2b trial results for DLB treatment
      Oct 29Investing.comCRVO
      CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
      Oct 29Yahoo FinanceCRVO
      CervoMed stock rating reiterated at Buy by H.C. Wainwright on biomarker data
      Oct 19Investing.comCRVO
      CervoMed Shows Progress in Treating Rare Aphasia Condition - CervoMed (NASDAQ:CRVO)

      CervoMed reports a promising reduction in neuronal damage biomarkers during the first 12 weeks of its Phase 2a trial for neflamapimod.

      Oct 12BenzingaCRVO
      CervoMed reports biomarker decline in dementia trial
      Oct 12Investing.comCRVO
      CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
      Oct 12Yahoo FinanceCRVO
      H.C. Wainwright reiterates Buy on CervoMed stock on new formulation
      Oct 5Investing.comCRVO
      CervoMed advances higher-dose neflamapimod formulation
      Sep 28Investing.comCRVO
      CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

      New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA removal of the prior drug exposure limit provides greater dosing flexibility in future clinical trials CervoMed plans to advance a 100 mg twice-daily regimen expected to achieve higher plasma trough drug concentrations than those associated with clinical activity in prior trials BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. ("CervoMed" or the "Company") (N

      Sep 28Yahoo FinanceCRVO
      CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

      BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 5th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Tuesday, September 29, 2026. Panel DetailsTitle: "Frontiers in Neuroscience"Date: Tuesday, September 29

      Sep 22Yahoo FinanceCRVO
      CervoMed at Cantor healthcare conference: phase iii path in focus
      Sep 11Investing.comCRVO
      CervoMed to present nfvPPA trial biomarker data at ISFTD meeting
      Sep 10Investing.comCRVO
      CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026

      12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting nfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology, currently has no approved treatments in the United States or European Union BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that neflamapimod, an ora

      Sep 10Yahoo FinanceCRVO
      CervoMed to Participate in September Investor Conferences

      BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), today announced that Company management will participate in the following investor conferences during the month of September: Cantor Global Healthcare Conference Format: Fireside Chat & 1x1 Investor MeetingsDate: Friday, September 11, 2026Time: 10:55 – 11:25 AM ET Webcast Link: https://sqps.onstreamsec

      Sep 8Yahoo FinanceCRVO

      This is the newest page. Registered accounts read further back.